Compugen Q1 Revenue $2.2M, Cash Sufficient Until 2029
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Reports Q1 revenue $2.2M vs. $2.3M last year. Compugen expects that its cash and cash-related balances will be sufficient to fund its operating plans into 2029. The company has no debt. "Q1 2026 reflects continued execution across all of our programs in line with our strategic priorities," said CEO Eran Ophir. "With enrollment progressing across all COM701 MAIA-ovarian trial sites, we remain on track for having the median progression-free survival at the interim analysis by Q1 2027, a key potential inflection point for COM701 as a maintenance therapy in a patient population with significant unmet medical need and no current standard of care. Our partner AstraZeneca continues to broadly advance rilvegostomig. In addition, we continue to advance the Gilead-partnered GS-0321 Phase 1 trial. Our solid financial position with cash runway expected into 2029, based on our current plans, enables us to advance our differentiated immuno-oncology pipeline and leverage our AI/ML powered computational discovery platform Unigen, to discover novel ways to activate the immune system against cancer. I remain encouraged by the progress of our fully owned programs, strengthened by validating partnerships with AstraZeneca and Gilead, which together offer approximately $1B in potential milestones plus royalties."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGEN
Wall Street analysts forecast CGEN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.020
Low
4.00
Averages
4.00
High
4.00
Current: 2.020
Low
4.00
Averages
4.00
High
4.00
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compugen Presents COM701 Progress at ESMO Congress
- Clinical Trial Progress: Compugen presented the progress of COM701 in the MAIA-ovarian adaptive platform trial at the 2026 ESMO Gynaecological Cancers Congress, highlighting the antibody's potential in relapsed platinum-sensitive ovarian cancer, with initial data expected by Q1 2027, which could introduce new treatment options in this field.
- Biological Rationale: CEO Eran Ophir, Ph.D., emphasized the strong biological and clinical rationale for the MAIA-ovarian trial, noting that COM701 has shown good tolerability and durable responses in platinum-resistant patients, indicating its promising application in treating relapsed platinum-sensitive ovarian cancer.
- Trial Design: The MAIA-ovarian trial (NCT06888921) aims to evaluate the safety and efficacy of COM701 as a maintenance therapy, showcasing Compugen's innovative capabilities in cancer immunotherapy, which could potentially alter existing treatment standards.
- Future Outlook: As the first-in-class anti-PVRIG antibody, COM701, combined with Compugen's AI/ML computational discovery platform, has demonstrated initial signs of anti-tumor activity, potentially driving the company's further development in the cancer immunotherapy market.
See More
Compugen to Present COM701 Progress at ESMO Congress
- Clinical Trial Update: Compugen will present the progress of its COM701 in the MAIA-ovarian Phase 1 clinical trial at the ESMO Gynaecological Cancers Congress on June 18, 2026, highlighting its potential application in relapsed platinum-sensitive ovarian cancer, which signifies the company's ongoing innovation in cancer immunotherapy.
- Speaker and Timing: The poster will be presented by Dr. Oladapo Yeku from Massachusetts General Hospital, scheduled from 12:45 to 13:30 CEST, demonstrating Compugen's commitment to transparency in clinical research and the importance of scientific communication.
- Innovative Drug Pipeline: Compugen's innovative immuno-oncology pipeline includes four clinical-stage programs such as COM701 and COM902, showcasing the company's strong capabilities in developing novel cancer therapeutics, particularly in both monotherapy and combination therapy applications.
- Partnership and Licensing: The exclusive licensing agreement with AstraZeneca for the development of rilvegostomig further strengthens Compugen's market position in cancer immunotherapy, while also providing potential revenue streams for the company.
See More
Compugen Joins AI Drug Development Fireside Chat Series
- Management Participation: Compugen's management will participate in Jones Trading's AI/ML drug development fireside chat on June 15, 2026, showcasing the company's leadership in cancer immunotherapy, which is expected to attract investor interest and enhance market confidence.
- Innovative Platform Introduction: Compugen utilizes its AI/ML-powered Unigen™ platform for novel drug target discovery, driving the development of cancer immunotherapies, demonstrating the company's ongoing commitment to technological innovation and competitive advantage.
- Clinical Trial Progress: Compugen's COM701 and COM902 are undergoing clinical trials for solid tumors, particularly the MAIA trial evaluating COM701 as a single-agent maintenance therapy in relapsed platinum-sensitive ovarian cancer, potentially offering new treatment options for patients.
- Collaborative Development Dynamics: Under an exclusive licensing agreement with AstraZeneca, rilvegostomig is being evaluated in multiple clinical trials, highlighting the strategic value of Compugen's drug development collaborations and further strengthening its market position.
See More
Compugen Reports Q1 2026 Financial Results and Corporate Update
- Strong Financial Position: As of March 31, 2026, Compugen reported approximately $134.9 million in cash and cash equivalents, indicating a solid financial foundation that supports operational plans into 2029, allowing continued advancement of its immuno-oncology pipeline.
- Slight Revenue Decline: The company generated approximately $2.2 million in revenue for Q1 2026, a minor decrease from $2.3 million in Q1 2025, reflecting fluctuations in revenue sources that necessitate attention to future growth strategies.
- Increased R&D Expenses: R&D expenses for Q1 2026 were approximately $6.9 million, up from $5.8 million in the same period of 2025, primarily due to rising clinical costs associated with the MAIA-ovarian trial, demonstrating the company's commitment to clinical development.
- Stable Net Loss: Compugen reported a net loss of approximately $7.7 million for Q1 2026, with a loss per share of $0.08, consistent with the previous year's results, indicating effective loss control while continuing to invest in R&D and operations.
See More
Compugen Q1 Earnings: Revenue Beats Expectations
- Revenue Performance: Compugen reported Q1 revenue of $2.18 million, a 4.4% year-over-year decline, yet it exceeded expectations by $0.92 million, indicating effective revenue management despite a challenging market environment.
- Earnings Per Share: The GAAP EPS of -$0.08 missed expectations by $0.01, reflecting pressure on profitability that could impact investor confidence and future stock performance.
- Cash Position: As of March 31, 2026, Compugen had approximately $134.9 million in cash and cash equivalents, which is expected to fund its operating plans into 2029, demonstrating financial stability and operational sustainability.
- Debt-Free Advantage: Compugen currently holds no debt, providing financial flexibility for future investments and expansions, thereby enhancing its competitive position within the industry.
See More
Compugen Scheduled to Announce Q1 Earnings on May 18
- Earnings Announcement: Compugen (CGEN) is set to release its Q1 2023 earnings on May 18 after market close, with a consensus EPS estimate of -$0.08, indicating ongoing challenges in profitability.
- Revenue Decline Expected: Analysts project revenue to be $1.26 million, reflecting a significant 45.2% year-over-year decline, highlighting competitive pressures and weak product sales.
- Historical Performance Review: Over the past two years, Compugen has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, indicating a degree of stability in its financial performance.
- Funding and Product Progress: Compugen has secured non-dilutive funding to support the development of Rilvegostomig and advance GS-0321, demonstrating proactive measures in research and funding management.
See More
Compugen Presents COM701 Progress at ESMO Congress
- Clinical Trial Progress: Compugen presented the progress of COM701 in the MAIA-ovarian adaptive platform trial at the 2026 ESMO Gynaecological Cancers Congress, highlighting the antibody's potential in relapsed platinum-sensitive ovarian cancer, with initial data expected by Q1 2027, which could introduce new treatment options in this field.
- Biological Rationale: CEO Eran Ophir, Ph.D., emphasized the strong biological and clinical rationale for the MAIA-ovarian trial, noting that COM701 has shown good tolerability and durable responses in platinum-resistant patients, indicating its promising application in treating relapsed platinum-sensitive ovarian cancer.
- Trial Design: The MAIA-ovarian trial (NCT06888921) aims to evaluate the safety and efficacy of COM701 as a maintenance therapy, showcasing Compugen's innovative capabilities in cancer immunotherapy, which could potentially alter existing treatment standards.
- Future Outlook: As the first-in-class anti-PVRIG antibody, COM701, combined with Compugen's AI/ML computational discovery platform, has demonstrated initial signs of anti-tumor activity, potentially driving the company's further development in the cancer immunotherapy market.
See More
Compugen to Present COM701 Progress at ESMO Congress
- Clinical Trial Update: Compugen will present the progress of its COM701 in the MAIA-ovarian Phase 1 clinical trial at the ESMO Gynaecological Cancers Congress on June 18, 2026, highlighting its potential application in relapsed platinum-sensitive ovarian cancer, which signifies the company's ongoing innovation in cancer immunotherapy.
- Speaker and Timing: The poster will be presented by Dr. Oladapo Yeku from Massachusetts General Hospital, scheduled from 12:45 to 13:30 CEST, demonstrating Compugen's commitment to transparency in clinical research and the importance of scientific communication.
- Innovative Drug Pipeline: Compugen's innovative immuno-oncology pipeline includes four clinical-stage programs such as COM701 and COM902, showcasing the company's strong capabilities in developing novel cancer therapeutics, particularly in both monotherapy and combination therapy applications.
- Partnership and Licensing: The exclusive licensing agreement with AstraZeneca for the development of rilvegostomig further strengthens Compugen's market position in cancer immunotherapy, while also providing potential revenue streams for the company.
See More
Compugen Joins AI Drug Development Fireside Chat Series
- Management Participation: Compugen's management will participate in Jones Trading's AI/ML drug development fireside chat on June 15, 2026, showcasing the company's leadership in cancer immunotherapy, which is expected to attract investor interest and enhance market confidence.
- Innovative Platform Introduction: Compugen utilizes its AI/ML-powered Unigen™ platform for novel drug target discovery, driving the development of cancer immunotherapies, demonstrating the company's ongoing commitment to technological innovation and competitive advantage.
- Clinical Trial Progress: Compugen's COM701 and COM902 are undergoing clinical trials for solid tumors, particularly the MAIA trial evaluating COM701 as a single-agent maintenance therapy in relapsed platinum-sensitive ovarian cancer, potentially offering new treatment options for patients.
- Collaborative Development Dynamics: Under an exclusive licensing agreement with AstraZeneca, rilvegostomig is being evaluated in multiple clinical trials, highlighting the strategic value of Compugen's drug development collaborations and further strengthening its market position.
See More
Compugen Reports Q1 2026 Financial Results and Corporate Update
- Strong Financial Position: As of March 31, 2026, Compugen reported approximately $134.9 million in cash and cash equivalents, indicating a solid financial foundation that supports operational plans into 2029, allowing continued advancement of its immuno-oncology pipeline.
- Slight Revenue Decline: The company generated approximately $2.2 million in revenue for Q1 2026, a minor decrease from $2.3 million in Q1 2025, reflecting fluctuations in revenue sources that necessitate attention to future growth strategies.
- Increased R&D Expenses: R&D expenses for Q1 2026 were approximately $6.9 million, up from $5.8 million in the same period of 2025, primarily due to rising clinical costs associated with the MAIA-ovarian trial, demonstrating the company's commitment to clinical development.
- Stable Net Loss: Compugen reported a net loss of approximately $7.7 million for Q1 2026, with a loss per share of $0.08, consistent with the previous year's results, indicating effective loss control while continuing to invest in R&D and operations.
See More
Compugen Q1 Earnings: Revenue Beats Expectations
- Revenue Performance: Compugen reported Q1 revenue of $2.18 million, a 4.4% year-over-year decline, yet it exceeded expectations by $0.92 million, indicating effective revenue management despite a challenging market environment.
- Earnings Per Share: The GAAP EPS of -$0.08 missed expectations by $0.01, reflecting pressure on profitability that could impact investor confidence and future stock performance.
- Cash Position: As of March 31, 2026, Compugen had approximately $134.9 million in cash and cash equivalents, which is expected to fund its operating plans into 2029, demonstrating financial stability and operational sustainability.
- Debt-Free Advantage: Compugen currently holds no debt, providing financial flexibility for future investments and expansions, thereby enhancing its competitive position within the industry.
See More
Compugen Scheduled to Announce Q1 Earnings on May 18
- Earnings Announcement: Compugen (CGEN) is set to release its Q1 2023 earnings on May 18 after market close, with a consensus EPS estimate of -$0.08, indicating ongoing challenges in profitability.
- Revenue Decline Expected: Analysts project revenue to be $1.26 million, reflecting a significant 45.2% year-over-year decline, highlighting competitive pressures and weak product sales.
- Historical Performance Review: Over the past two years, Compugen has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, indicating a degree of stability in its financial performance.
- Funding and Product Progress: Compugen has secured non-dilutive funding to support the development of Rilvegostomig and advance GS-0321, demonstrating proactive measures in research and funding management.
See More
